BiotechTube

rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Hypercholesterolaemia

Conditions

Familial Hypercholesterolaemia

Trial Timeline

Feb 1, 2010 → Feb 1, 2013

NCT ID
NCT01078675

About rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium

rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium is a phase 3 stage product being developed by AstraZeneca for Familial Hypercholesterolaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01078675. Target conditions include Familial Hypercholesterolaemia.

What happened to similar drugs?

5 of 20 similar drugs in Familial Hypercholesterolaemia were approved

Approved (5) Terminated (4) Active (13)
✅EvolocumabAmgenApproved
✅evolocumabAmgenApproved
✅AnakinraSwedish Orphan BiovitrumApproved
✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved
✅PraluentSanofiApproved
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01078675Phase 3Completed

Competing Products

20 competing products in Familial Hypercholesterolaemia

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
40
FluvastatinNovartisPhase 3
40